Guardion Health Sciences, Inc. (GHSI)
USD 3.22
(0.0%)
USD 3.22
(0.0%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 12.24 Million USD | 10.85% |
| 2022 | 11.04 Million USD | 52.77% |
| 2021 | 7.23 Million USD | 282.74% |
| 2020 | 1.88 Million USD | 109.3% |
| 2019 | 902.93 Thousand USD | -4.16% |
| 2018 | 942.15 Thousand USD | 115.42% |
| 2017 | 437.34 Thousand USD | 210.11% |
| 2016 | 141.02 Thousand USD | 25.01% |
| 2015 | 112.81 Thousand USD | -31.46% |
| 2014 | 164.58 Thousand USD | -36.79% |
| 2013 | 260.35 Thousand USD | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q2 | 72.91 Thousand USD | -97.57% |
| 2024 Q1 | 2.99 Million USD | 2.17% |
| 2023 Q3 | 3.33 Million USD | 19.62% |
| 2023 FY | 12.24 Million USD | 10.85% |
| 2023 Q1 | 3.18 Million USD | 16.85% |
| 2023 Q2 | 2.78 Million USD | -12.43% |
| 2023 Q4 | 2.93 Million USD | -12.03% |
| 2022 Q2 | 3.27 Million USD | 37.35% |
| 2022 Q1 | 2.38 Million USD | -9.24% |
| 2022 FY | 11.04 Million USD | 52.77% |
| 2022 Q4 | 2.72 Million USD | 2.36% |
| 2022 Q3 | 2.66 Million USD | -18.68% |
| 2021 FY | 7.23 Million USD | 282.74% |
| 2021 Q2 | 1.22 Million USD | 424.53% |
| 2021 Q1 | 233.29 Thousand USD | 16.63% |
| 2021 Q3 | 3.14 Million USD | 157.3% |
| 2021 Q4 | 2.62 Million USD | -16.55% |
| 2020 Q1 | 245.72 Thousand USD | 3.13% |
| 2020 Q3 | 253.18 Thousand USD | -78.74% |
| 2020 Q4 | 200.02 Thousand USD | -21.0% |
| 2020 FY | 1.88 Million USD | 109.3% |
| 2020 Q2 | 1.19 Million USD | 384.66% |
| 2019 Q2 | 260.97 Thousand USD | 7.6% |
| 2019 Q3 | 161.16 Thousand USD | -38.25% |
| 2019 Q4 | 238.26 Thousand USD | 47.84% |
| 2019 FY | 902.93 Thousand USD | -4.16% |
| 2019 Q1 | 242.53 Thousand USD | 3.6% |
| 2018 Q4 | 234.1 Thousand USD | -20.43% |
| 2018 Q3 | 294.23 Thousand USD | 33.27% |
| 2018 Q2 | 220.77 Thousand USD | 14.37% |
| 2018 Q1 | 193.04 Thousand USD | -25.39% |
| 2018 FY | 942.15 Thousand USD | 115.42% |
| 2017 FY | 437.34 Thousand USD | 210.11% |
| 2017 Q4 | 258.73 Thousand USD | 312.68% |
| 2017 Q3 | 62.69 Thousand USD | 4.54% |
| 2017 Q2 | 59.97 Thousand USD | 7.21% |
| 2017 Q1 | 55.94 Thousand USD | 14.55% |
| 2016 Q1 | 29.13 Thousand USD | 12.02% |
| 2016 FY | 141.02 Thousand USD | 25.01% |
| 2016 Q4 | 48.83 Thousand USD | 45.01% |
| 2016 Q3 | 33.67 Thousand USD | 14.61% |
| 2016 Q2 | 29.38 Thousand USD | 0.86% |
| 2015 FY | 112.81 Thousand USD | -31.46% |
| 2015 Q3 | 27.03 Thousand USD | -9.51% |
| 2015 Q2 | 29.88 Thousand USD | -0.0% |
| 2015 Q1 | 29.88 Thousand USD | -6.4% |
| 2015 Q4 | 26 Thousand USD | -3.81% |
| 2014 Q4 | 31.92 Thousand USD | 0.0% |
| 2014 FY | 164.58 Thousand USD | -36.79% |
| 2013 FY | 260.35 Thousand USD | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Bright Green Corporation | 401.49 Thousand USD | -2950.766% |
| BioQuest Corp. | - USD | -Infinity% |
| Clever Leaves Holdings Inc. | 17.41 Million USD | 29.675% |
| Eagle Pharmaceuticals, Inc. | 316.61 Million USD | 96.131% |
| GSRX Industries Inc. | - USD | -Infinity% |
| High Sierra Technologies, Inc. | - USD | -Infinity% |
| Instadose Pharma Corp. | - USD | -Infinity% |